Baxter’s REVACLEAR Dialyzer May Offer New Benefits
A new study of 37,500 HD patient records found that use of a REVACLEAR high flux dialyzer was linked to the need for 100 to 600 fewer units of ESA per treatment than matched patients who used an Optiflux® 160 or 180 dialyzer. Researchers also noted a trend toward lower IV iron doses with the Revaclear—while keeping the same HD dose and hemoglobin level.
Read the full article » | Posted 08-09-2016
Related Articles
- Education Critical to Boosting Home Dialysis, Panel Says I Posted 01-16-2026
- The Annual Dialysis Conference Will be in Kansas City, MO February 26 to March 1 Posted 01-16-2026
- The Forum of ESRD Networks has New Videos for its 2023 Home Dialysis Toolkit Posted 01-16-2026
- Vantive: Real People, Real Stories on PD Empowers Site for Patients Posted 12-17-2025

